Ionis Pharmaceuticals Inc (FRA:ISI)
€ 33.48 -0.13 (-0.39%) Market Cap: 5.40 Bil Enterprise Value: 4.42 Bil PE Ratio: 0 PB Ratio: 8.55 GF Score: 60/100

Ionis Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript

Nov 28, 2023 / 03:00PM GMT
Release Date Price: €45.32 (+1.41%)
Allison Marie Bratzel
Piper Sandler & Co., Research Division - VP and Senior Research Analyst

Let's go ahead and get started. So thanks, everyone, for joining us. My name is Ally Bratzel, one of the senior biotech analysts here at Piper Sandler, and it's my pleasure to introduce this morning Ionis. So joining us today, we have Brett Monia, CEO. So thanks for joining.

Just to go over the format, this is meant to be informal. If anyone in the audience has a question, feel free, just raise your hand, speak up, and we will get your question asked.

Questions & Answers

Allison Marie Bratzel
Piper Sandler & Co., Research Division - VP and Senior Research Analyst

But I will go ahead and get us started off. I have a couple of pages worth of questions here. So maybe, Brett, just kind of an intro question. I think we all know Ionis has a long history as a leading antisense and ASO company. So just to kick us off, go over the evolution of your key late-stage programs, eplontersen, donidalorsen and olezarsen, how that fits in the Ionis

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot